Arcturus Therapeutics

ARCT

Market cap $251M

Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.

Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events secti.

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.11 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. “Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the orn.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3.

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found.

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.